<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02498587</url>
  </required_header>
  <id_info>
    <org_study_id>ANZIC-RC/SW0002</org_study_id>
    <nct_id>NCT02498587</nct_id>
  </id_info>
  <brief_title>Short Period Incidence Study of Severe Acute Respiratory Illness</brief_title>
  <acronym>SPRINT-SARI</acronym>
  <official_title>Short Period Incidence Study of Severe Acute Respiratory Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Australian and New Zealand Intensive Care Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Severe Acute Respiratory and Emerging Infection Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The International Forum of Acute Care Trialists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Australian and New Zealand Intensive Care Research Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, prospective, short period incidence observational study of patients
      in participating hospitals and intensive care units (ICUs) with SARI. The study period will
      occur, in both Northern and Southern hemispheric winters. The study period will comprise a 5
      to 7-day cohort study in which patients meeting a SARI case-definition, who are newly
      admitted to the hospitals / ICUs at participating sites, will be included in the study. The
      study will be conducted in 20 to 40-hospital/ ICU-based research networks globally. All
      clinical information and sample data will only be recorded if taken as part of the routine
      clinical practice at each site and only fully anonymised and de-identified data will be
      submitted centrally.

      The primary aim of this study is to establishing a research response capability for a future
      epidemic / pandemic through a global SARI observational study. The secondary aim of this
      study is to investigate the descriptive epidemiology and microbiology profiles of patients
      with SARI. The tertiary aim of this study is to assess the Ethics, Administrative, Regulatory
      and Logistic (EARL) barriers to conducting pandemic research on a global level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe acute respiratory infection (SARI) continues to be of major relevance to public health
      worldwide. In the last 10 years there have been multiple SARI outbreaks around the world. The
      2009 H1N1 pandemic was estimated to result in more than 200,000 respiratory deaths globally.
      The World Health Organization (WHO) defines SARI as an acute respiratory infection of recent
      onset (within 10 days) requiring hospitalisation, manifested by fever (≥38oC) or a history of
      fever and cough. There is international consensus that it is important to undertake
      observational studies of patients with SARI as an essential component of pandemic and
      epidemic research preparedness.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participating sites</measure>
    <time_frame>one week</time_frame>
    <description>The number of sites able to participate and submit data for central analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Data Completeness</measure>
    <time_frame>90 days</time_frame>
    <description>The completeness of submitted data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Barriers to data submission</measure>
    <time_frame>90 days</time_frame>
    <description>Survey post SPRINT-SARI study period on barriers to data completion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of SARI</measure>
    <time_frame>one week</time_frame>
    <description>Number of participants during the study period at all sites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>90 days</time_frame>
    <description>Length of stay of SARI patients by co-morbidities and risk factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms at admission</measure>
    <time_frame>90 days</time_frame>
    <description>Impact of different SARI case definitions on cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Intensive Care Unit Admission</measure>
    <time_frame>90 days</time_frame>
    <description>Rate of ICU admission in SARI cohorts and international variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit Admission</measure>
    <time_frame>90 days</time_frame>
    <description>Length of stay for participants admitted to an ICU during SARI hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARI Microbiology</measure>
    <time_frame>90 days</time_frame>
    <description>Microbiological SARI diagnosis of participants (if known) during hospital admission</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Global Ethical Approval requirements</measure>
    <time_frame>90 days</time_frame>
    <description>Survey post SPRINT-SARI study period of ethical approval requirements in participating countries</description>
  </other_outcome>
  <other_outcome>
    <measure>Time requirements for obtaining Ethical approval</measure>
    <time_frame>90 days</time_frame>
    <description>Survey post SPRINT-SARI study period of time required to obtain ethical approval for SPRINT-SARI at participating sites</description>
  </other_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Severe Acute Respiratory Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients newly admitted to participating hospitals, of any age, presenting with SARI
        during the study period. Patients will be eligible for the study if the patient meets the
        case definition for SARI.

        A suspected or proven acute respiratory infection requiring new inpatient admission with
        onset within the past 14 days. With one or more of the inclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A history of feverishness or measured fever of ≥ 38 deg C;

          -  Cough;

          -  Dyspnoea (shortness of breath) OR Tachypnoea.

        Exclusion Criteria:

        • No exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maya George, PhD</last_name>
    <phone>450974042</phone>
    <email>Maya.George@monash.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Australian and New Zealand Intensive Care Research Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya George</last_name>
      <phone>+61 3 99030217</phone>
      <email>maya.george@monash.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lynne Murray</last_name>
      <phone>+61 3 99030347</phone>
      <email>lynne.murray@monash.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Webb</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>J.Perren Cobb</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rob Fowler</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colin McArthur</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Srinivas Murthy</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alistair Nichol</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachael Parke</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eoin West</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Woni-il Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Calum Semple</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beth Riviello</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence Pradel</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Guillebaud</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Behzad Nadjm</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evangelos Giamerellos</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre Demoule</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mia Valkonein</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annane Djillali</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Santiago Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2015</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe Acute Respiratory Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

